Amgen is planning to invest $200m to construct a manufacturing facility in the Tuas Biomedical Park area of Singapore.
Company intends to begin the construction of the new facility shortly to expand the monoclonal antibody manufacturing capacity.
Amgen operations executive vice president Madhu Balachandran said the planning for the new Singapore facility is a part of the strategic global expansion.
“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” Balachandran added.
New facility, which is expected to employ fresh recruits along with experienced staff, will manufacture both clinical and commercial products.